Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
Holding ADAP?
Track your performance easily

Adaptimmune Therapeutics (ADAP) Financial Statements

797 Followers

Adaptimmune Therapeutics Financial Overview

Adaptimmune Therapeutics's market cap is currently ―. The company's EPS TTM is $-0.345; its P/E ratio is -2.24; Adaptimmune Therapeutics is scheduled to report earnings on November 13, 2024, and the estimated EPS forecast is $-0.01. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 128.23M$ 5.68M$ 231.00K$ 7.32M$ 5.13M
Gross Profit$ 128.23M$ 5.68M$ 231.00K$ 7.32M$ 5.13M
EBIT$ 70.05M$ -47.98M$ -49.86M$ -46.63M$ -20.71M
EBITDA$ 72.77M$ -45.17M$ -46.98M$ -43.74M$ -19.22M
Net Income Common Stockholders$ 69.52M$ -48.50M$ -47.92M$ -45.60M$ -21.39M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 214.79M$ 143.65M$ 146.94M$ 161.73M$ 204.71M
Total Assets$ 321.70M$ 258.01M$ 282.62M$ 296.64M$ 342.98M
Total Debt$ 47.35M$ 23.69M$ 25.23M$ 25.60M$ 26.34M
Net Debt$ -167.44M$ -119.96M$ -121.70M$ -136.13M$ -178.37M
Total Liabilities$ 225.43M$ 233.63M$ 243.10M$ 208.51M$ 216.33M
Stockholders Equity$ 96.27M$ 24.38M$ 39.51M$ 88.13M$ 126.65M
Cash Flow-
Free Cash Flow$ 46.66M$ -32.31M$ -15.50M$ -45.45M$ -44.47M
Operating Cash Flow$ 47.40M$ -31.95M$ -14.68M$ -45.16M$ -43.76M
Investing Cash Flow$ -743.00K$ -358.00K$ 68.20M$ 57.31M$ 2.69M
Financing Cash Flow$ 24.51M$ 29.23M$ 74.00K$ 596.00K$ 14.00K
Currency in USD

Adaptimmune Therapeutics Earnings and Revenue History

Adaptimmune Therapeutics Debt to Assets

Adaptimmune Therapeutics Cash Flow

Adaptimmune Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis